The impact of the COVID-19 infection epidemic on the provision of health care for people living with HIV
- Authors: Ladnaia N.N.1, Kozyrina N.V.1, Babikhina K.A.2, Mikhailov A.V.2, Egorova N.V.2, Godlevskaya M.V3, Semenchenko M.V.4, Zograbyan L.S.4, Pokrovsky V.V.1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- Treatment Preparedness Coalition
- «E.B.A.» Association
- UNAIDS Regional Office for Eastern Europe and Central Asia
- Issue: Vol 11, No 3 (2021)
- Pages: 19-27
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287774
- DOI: https://doi.org/10.18565/epidem.2021.11.3.19-27
- ID: 287774
Cite item
Abstract
Full Text
About the authors
Natalia N. Ladnaia
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: nladnaia@hotmail.com
Cand. Biol. Sci., Senior Researcher
Nadezhda V. Kozyrina
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: nad-kozyrina@yandex.ru
Cand. Med. Sci., Researcher
Ksenia A. Babikhina
Treatment Preparedness Coalition
Email: kbabikhina@itpcru.org
Monitoring Expert
Alexey V. Mikhailov
Treatment Preparedness Coalition
Email: aleksey.mikhailov@itpcru.org
Head of Monitoring Section
Natalia V. Egorova
Treatment Preparedness Coalition
Email: egorova@itpcru.org
Monitoring Expert
M. V Godlevskaya
«E.B.A.» Association
Email: m.godlevskaya@gmail.com
Marina V. Semenchenko
UNAIDS Regional Office for Eastern Europe and Central Asia
Email: semenchenkom@unaids.org
Cand. Med. Sci., Regional Adviser
Lev S. Zograbyan
UNAIDS Regional Office for Eastern Europe and Central Asia
Email: zohrabyanl@unaids.org
Cand. Med. Sci., Strategic Information Adviser
Vadim V. Pokrovsky
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: pokrovsky.vad@yandex.ru
Academician of the Russian Academy of Sciences, MD, Head, HIV Department
References
- Coronavirus disease ( COVID-19) Situation Report - 163. Data as received by WHO from national authorities by 10:00 CEST, 1 July 2020. WHO, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701- COVID-19-sitrep-163.pdf?sfvrsn=c202f05b_2
- COVID-19 Weekly Epidemiological Update. Edition 46, published 29 June 2021. WHO, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-oncovid-19-29-june-2021
- Информационный бюллетень 2021 г. Предварительные эпидемиологические оценочные данные. ЮНЭЙДС, 2021. https://www.unaids.org/ru/resources/fact-sheet [Global HIV & AIDS statistics. Fact sheet, 2021. HIV ESTIMATES]. UNAIDS, 2021. https://www.unaids.org/ru/resources/fact-sheet
- Blanco J.L., Ambrosioni J., Garcia F., Martinez E., Soriano A., Mallolas J. et al. COVID-19 in HIV Investigators. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; Apr 15. pii: S2352-3018(20)30111-9
- Harter G., Spinner C.D., Roider J., Bickel M., Krznaric I., Grunwald S. et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection 2020, May 11. doi: 10.1007/s15010-020-01438-z
- Gervasoni C., Meraviglia P., Riva A., Giacomelli A., Oreni L., Minisci D. et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin. Infect. Dis. 2020, May 14. pii: ciaa579. doi: 10.1093/cid/ciaa579
- Guo W., Ming F., Dong Y. et al. A Survey for COVID-19 among HIV/AIDS Patients in Two Districts of Wuhan, China. Preprint research paper, The Lancet, 2020.
- Wu Q., Chen T., Zhang H. Recovery from COVID-19 in two patients with coexisted HIV infection. J. Med. Virol. 2020, May 13. doi: 10.1002/jmv.26006
- Karmen-Tuohy S., Carlucci P.M., Zacharioudakis I.M., Zervou F.N., Rebick G. et al. Outcomes among HIV-positive patients hospitalized with COVID-19. medRxiv. https://www.medrxiv.org/content/10.1101/2020.05.07.20094797v1
- Docherty A.B., Harrison E.M., Green C.A. et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterization protocol. medRxiv preprint. DOI: https://doi.org/10.1101/2020.04.23.20076042
- Inciartea A., Gonzalez-Cordona A., Rojasa J. et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS 2020; 34(12): 1775-1780. doi: 10.1097/QAD. 0000000000002643
- Gao Z., Xu Y., Sun C., Wang X., Guo Y., Qiu S. et al. A systematic review of asymptomatic infections with COVID-19. J. Microbiol. Immunol. Infect. 202010.1016/j. jmii.2020.05.001. doi: 10.1016/j.jmii.2020.05.001
- Wang Q.Q., Kaelber D.C. Xu, R. et al. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol. Psychiatry (2020). https://doi.org/10.1038/s41380-020-00880-7
- Ssentongo P., Heilbrunn E.S., Ssentongo A.E. et al. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: a systematic review and meta-analysis. Presented at: IDWeek 2020; October 21-25, 2020. Poster 393. https://www.infectiousdiseaseadvisor.com/home/meetings/idweek-2020-hiv-in-depth/people-with-hiv-higher-susceptibility-and-mortality-to-coronavirus-in-us/
- Дробышевская Е.В., Жукова Е.В., Ватулян А.К. Клинико-эпидемиологическая характеристика пациентов с сочетанной патологией ВИЧ + COVID-19 в Московской области. Сборник тезисов VIII Конгресса с международным участием «Контроль и профилактика инфекций, связанных с оказанием медицинской помощи (ИСМП-2020)». М.: ЦНИИ эпидемиологии Роспотребнадзора, 2020
- Cao B., Wang Y., Wen D. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19. N. Engl. J. Med. 2020. doi: 10.1056/NEJMoa2001282
- Q&A: HIV, antiretrovirals and COVID-19? WHO, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-on-COVID-19-hiv-and-antiretrovirals